In Battle of HPV Assays, Opinions Differ on Relative Importance of Sensitivity and Genotyping | GenomeWeb

NEW YORK (GenomeWeb) – A recent evaluation of FDA-approved molecular HPV screening assays from Roche, Hologic, and Qiagen has found that the three tests showed variations in which samples tested positive or negative. These disparate results point to an obvious question: would it would be worse to receive a falsely positive result or a negative result when an individual is actually infected with a high-risk viral strain?

It appears the answer to that question will remain a matter of debate among the makers of those tests and researchers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.